What Happens If Your Job Drops GLP-1 Coverage in 2027

The Business Group on Health released a survey in June 2026 that put hard numbers on something patients and employers had been quietly worrying about all year. Among the 105 large US employers polled, 67% currently cover GLP-1 drugs like Wegovy, Zepbound, and Foundayo for obesity. About 10% of the employers currently providing that coverage said they expect to drop it in 2027.

That sounds like a small share, but it matters. Large employers with self-funded health plans cover roughly 100 million Americans. A 10% pullback among employers who currently cover GLP-1s could mean 1 to 3 million patients lose access through their work-based insurance over the next 12 to 18 months, depending on plan size and benefit structure.

The reason isn't surprising. GLP-1 drug spending has kept climbing through 2026 even though per-unit drug prices have fallen from where they were in 2024. The driver is utilization. Lilly's Foundayo (oral GLP-1, approved April 2026) and Novo's Wegovy pill (approved January 2026) made GLP-1 therapy accessible to people who would never have started an injection. Those new patients aren't replacing existing users; they're adding to total demand. Costs scale with the number of patients, not with the price per dose.

To understand what's at risk, it helps to know how GLP-1s are usually paid for in 2026.

For people with employer-sponsored insurance, the standard path looks like this. Your employer's health plan covers a portion of the drug cost. The pharmacy benefit manager (PBM), companies like CVS Caremark, Express Scripts, or OptumRx, negotiates the price the plan pays. Manufacturer copay cards bring your out-of-pocket cost to as low as $25 a month. That layered system has been the backbone of GLP-1 access for most US patients with private insurance.

If your employer drops coverage, all four layers come apart. The plan no longer pays its share. The PBM-negotiated price no longer applies. And most manufacturer copay programs require you to have commercial insurance coverage to be eligible. Even keeping the same prescription, you can go from a $25-a-month copay to paying full retail price almost overnight.

Employers are pulling back for one big reason: the math has changed.

In 2024, when GLP-1s were primarily injectable and the patient population was relatively small, total annual drug spending on obesity drugs was manageable for most large self-funded plans. By 2026, two things shifted at once.

First, the drugs got easier to start. The Wegovy pill (January 2026) and Foundayo (April 2026) eliminated the injection barrier that had kept a wide cohort of obesity patients away from GLP-1 therapy. Patients who had never been willing to do a weekly shot were now willing to try a daily pill. Utilization climbed faster than employers had projected.

Second, per-unit prices fell while total spending kept rising. Lilly cut LillyDirect Zepbound vial prices in December 2025. The TrumpRx most-favored-nation deal landed at $346 per month for injectable GLP-1s, trending to $245. CVS Caremark added Foundayo to its commercial formulary in June 2026 at terms that brought patient copays as low as $25. Per dose, GLP-1s got cheaper. Per patient, they stayed expensive enough that more patients on therapy meant more total cost.

By spring 2026, large employers were looking at GLP-1 spending lines that had grown 40 to 60% year over year. The math on continuing full coverage stopped working for some of them.

If your employer drops coverage, you have five main options to keep your GLP-1 access. Each comes with different prices, different eligibility rules, and different practical considerations.

Option 1: TrumpRx (the federal direct-to-consumer route). The Trump administration's most-favored-nation pricing deal with Lilly and Novo gives uninsured patients direct access to GLP-1s. Oral GLP-1s like Foundayo and Wegovy pill cost $150 a month for starter doses. Injectable GLP-1s like Wegovy and Zepbound run $346 a month at launch, with the agreement trending the price down to $245 a month over two years. No insurance required. The trade-off: you pay the full TrumpRx price without any copay assistance.

Option 2: Medicare GLP-1 Bridge (if you qualify). The Medicare Bridge program launches July 1, 2026 and runs through December 31, 2027. Eligible Part D beneficiaries pay $50 a month for Wegovy, Zepbound, or Foundayo, and Medicare picks up the rest at a negotiated price of roughly $245 a month. Eligibility requires BMI 30 or higher with at least one weight-related comorbidity, or BMI 27 or higher with pre-diabetes or established cardiovascular disease. You also need to be enrolled in a participating Part D plan; state Medicaid programs can opt in through January 1, 2027.

Option 3: LillyDirect or NovoCare self-pay. Both manufacturers run direct-to-consumer self-pay programs. NovoCare's Wegovy injectable runs $349 a month for the standard 2.4 mg dose, $399 for the newer 7.2 mg HD dose, and $149 for the Wegovy pill 1.5 mg or 4 mg starter doses. LillyDirect Zepbound vials run $299 for the 2.5 mg starter, $399 for 5 mg, and $449 for the 7.5 to 15 mg maintenance doses. These prices don't change based on whether you have insurance, so the self-pay channel is your floor if employer coverage and savings cards aren't options.

Option 4: Manufacturer copay programs (if you have other commercial insurance). If you keep commercial insurance through a spouse, a state marketplace plan, or a new employer, the manufacturer copay cards can bring your monthly cost as low as $25. Wegovy.com runs a savings offer for commercially insured patients; LillyDirect offers similar terms for Zepbound and Foundayo. Medicare and Medicaid patients are excluded from these programs because federal anti-kickback rules limit drug-maker copay assistance to government beneficiaries.

Option 5: Compounded GLP-1s (closing fast). The compounded-GLP-1 channel through 503A pharmacies still operates as of June 2026, with monthly costs in the $159 to $349 range depending on dose and drug. The 503B outsourcing-facility channel closes after the FDA's June 29 comment window finalizes; large-scale compounding ends shortly after. The 503A path is also under regulatory pressure as the FDA tightens its position on telehealth-channel marketing. The compounded route is not a long-term plan for most patients.

For employees whose employers keep covering GLP-1s, the survey reveals another change worth knowing about. Companies that continue coverage are layering on management strategies to control costs:

• Required weight-management program participation: a growing share of plans now require enrollees to participate in a structured weight-loss support program before, during, or as a condition of GLP-1 coverage.
• Biometric eligibility verification: BMI, A1C, and comorbidity documentation are increasingly required at intake and at renewal, rather than only at the start of treatment.
• Restricted prescribing: some plans now only cover GLP-1s prescribed by an endocrinologist, bariatric specialist, or designated obesity-medicine provider; primary-care prescriptions can be excluded.

These management strategies mean that even employees on a covered plan may find access more restricted in 2027 than it was in 2024 or 2025. If your employer is among the 67% planning to continue coverage, talk to your benefits team about whether any of these gates are being added for the next plan year.

If you're on a GLP-1 through employer insurance and you're worried about losing coverage in 2027, here are practical steps to take before open enrollment.

Check your employer's 2027 benefits announcement when it lands. Most large employers release 2027 benefit summaries in October or November 2026 for open enrollment. Look specifically for the GLP-1 coverage line, the prior-authorization requirements, and any new management-strategy gates. Don't assume the 2026 coverage will continue.

Document medical necessity now. Work with your prescriber to keep an updated record of your BMI, your comorbidities, your initial GLP-1 response, and any cardiovascular or kidney indications. If you have to switch payers, prior-authorization is faster when documentation is complete.

Map your 2027 cost across the five options. Pick the dose you're on. Calculate your monthly cost under TrumpRx, LillyDirect/NovoCare self-pay, and Medicare Bridge (if you'd qualify). Add the manufacturer copay program if you'd have alternative commercial insurance. This is your worst-case-cost scenario.

Check Medicare or Medicaid eligibility if you're close. The Medicare Bridge covers Wegovy, Zepbound, and Foundayo at $50 a month, but only for eligible Part D beneficiaries. If you turn 65 in 2026 or 2027, or if you have a qualifying disability, the Bridge may be your cheapest option.

Don't drop the drug abruptly. The 2026 SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN Phase 3 data published in May confirmed what real-world patients already knew: stopping a GLP-1 leads to weight regain in roughly two-thirds of patients within 18 months. If you have to transition between payers, work with your prescriber to bridge the gap rather than stopping cold.

The 2027 coverage cliff is the first major demand-destruction risk for the GLP-1 obesity market. Lilly and Novo have been preparing for it. Both companies built direct-to-consumer pricing channels (LillyDirect, NovoCare) precisely to capture the patients employer plans stop covering. The TrumpRx deal extended that hedge to the uninsured. The Medicare Bridge captures the eligible-Medicare population. And manufacturer copay programs keep the commercially insured tier at $25.

For PBMs, the picture is more uncertain. CVS Caremark's June 2026 deal with Lilly to bring Foundayo and Zepbound under standard formulary at $25 copays was partly an effort to keep employer plans interested in coverage. If a meaningful share of employers drop anyway, the PBMs lose volume.

For patients, the practical implication is simpler: GLP-1 access in 2027 will increasingly depend on which government, manufacturer, or direct-to-consumer channel works for you, rather than on whether your employer chose to cover the drug. The era of employer-sponsored coverage being the default for obesity drugs is already shifting.